Evaluation of glycemic control in patients with type 2 diabetes mellitus in Chinese communities: a cross-sectional study

Clinical and Experimental Medicine

Volumn 17, Issue 1, 2017, Pages 79-84

  Shan, Shan ^a,b   Gu, Liubao ^a,b   Lou, Qinglin ^a,b   Ouyang, Xiaojun ^a,b   Yu, Yun ^a,b   Wu, Haidi ^a,b   Bian, Rongwen ^a,b  

^a BEIJING HOSPITAL   (China)

^b Jiangsu Province Official Hospital   (China)

Author keywords

China; Community management; Glycemic control; Type 2 diabetes mellitus

Indexed keywords

ANTIDIABETIC AGENT; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; INSULIN;

AGED; ARTICLE; CHINESE; CHOLESTEROL BLOOD LEVEL; COMMUNITY; CREATININE BLOOD LEVEL; CROSS-SECTIONAL STUDY; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SEX DIFFERENCE; VIBRATION SENSE; WAIST CIRCUMFERENCE; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD; DIABETES MELLITUS, TYPE 2; DIABETIC DIET; DIET RESTRICTION; DISEASE MANAGEMENT; DRUG MONITORING; ETHNOLOGY; EXERCISE; METABOLISM; MIDDLE AGED; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BIOMARKERS; BLOOD GLUCOSE; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DIET, DIABETIC; DISEASE MANAGEMENT; DRUG MONITORING; EXERCISE; FASTING; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LOGISTIC MODELS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84951816386     PISSN: 15918890     EISSN: 15919528     Source Type: Journal    
DOI: 10.1007/s10238-015-0406-x     Document Type: Article

References (22)

1. Xu Y, Wang L, He J, et al. Prevalence and control of diabetes in Chinese adults. JAMA. 2013;310:948–59.
2. Rothschild SK, Martin MA, Swider SM, et al. Mexican american trial of community health workers: a randomized controlled trial of a community health worker intervention for mexican americans with type 2 diabetes mellitus. Am J Public Health. 2014;104:1540–8.
3. Coburn KD, Marcantonio S, Lazansky R, Keller M, Davis N. Effect of a community-based nursing intervention on mortality in chronically ill older adults: a randomized controlled trial. PLoS Med. 2012;9:e1001265.
4. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the study of diabetes. Diabetologia. 2009;52:17–30.
5. Braga M, Casanova A, Teoh H, et al. Treatment gaps in the management of cardiovascular risk factors in patients with type 2 diabetes in Canada. Can J Cardiol. 2010;26:297–302.
6. Chinese Diabetes Society. Guidelines of prevention and treatment for Chinese type 2 diabetes. Chin J Diabetes. 2012;20:S1–37 (in Chinese).
7. Dailey G. Early and intensive therapy for management of hyperglycemia and cardiovascular risk factors in patients with type 2 diabetes. Clin Ther. 2011;33:665–78.
8. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383–93.
9. Hogan P, Dall T, Nikolov P. American Diabetes Association. Economic costs of diabetes in the US in 2002. Diabetes Care. 2003;26:917–32.
10. Sazlina SG, Mastura I, Ahmad Z, et al. Control of glycemia and other cardiovascular disease risk factors in older adults with type 2 diabetes mellitus: data from the Adult diabetes control and management. Geriatr Gerontol Int. 2014;14:130–7.
11. de Pablos-Velasco P, Parhofer KG, Bradley C, et al. Current level of glycaemic control and its associated factors in patients with type 2 diabetes across Europe: data from the PANORAMA study. Clin Endocrinol (Oxf). 2014;80:47–56.
12. Munshi MN, Segal AR, Suhl E, et al. Frequent hypoglycemia among elderly patients with poor glycemic control. Arch Intern Med. 2011;171:362–4.
13. Ismail-Beigi F. Clinical practice. Glycemic management of type 2 diabetes mellitus. N Engl J Med. 2012;366:1319–27.
14. Ahtiainen M, Alen M, Pollanen E, et al. Hormone therapy is associated with better body composition and adipokine/glucose profiles: a study with monozygotic co-twin control design. Menopause. 2012;19:1329–35.
15. Smith NL, Savage PJ, Heckbert SR, et al. Glucose, blood pressure, and lipid control in older people with and without diabetes mellitus: the Cardiovascular Health Study. J Am Geriatr Soc. 2002;50:416–23.
16. Akbar DH, Al-Gamdi AA, Hejazi NA. Poor lipid control in type-2 diabetics with and without ischemic heart disease. Endocrine. 2003;21:217–20.
17. Al Sifri SN, Almahmeed W, Azar S, et al. Results of the dyslipidemia international study (DYSIS)-middle east: clinical perspective on the prevalence and characteristics of lipid abnormalities in the setting of chronic statin treatment. PLoS One. 2014;9:e84350.
18. Benoit SR, Fleming R, Philis-Tsimikas A, Ji M. Predictors of glycemic control among patients with Type 2 diabetes: a longitudinal study. BMC Public Health. 2005;5:36.
19. Willey CJ, Andrade SE, Cohen J, Fuller JC, Gurwitz JH. Polypharmacy with oral antidiabetic agents: an indicator of poor glycemic control. Am J Manag Care. 2006;12:435–40.
20. Pan C, Yang W, Jia W, Weng J, Tian H. Management of Chinese patients with type 2 diabetes, 1998–2006: the Diabcare-China surveys. Curr Med Res Opin. 2009;25:39–45.
21. Tan MY, Magarey J. Self-care practices of Malaysian adults with diabetes and sub-optimal glycaemic control. Patient Educ Couns. 2008;72:252–67.
22. Zhu VJ, Tu W, Marrero DG, Rosenman MB, Overhage JM. Race and medication adherence and glycemic control: findings from an operational health information exchange. AMIA Annu Symp Proc. 2011;2011:1649–57.